Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
AVLV vs IBB: how they differ
AVLV and IBB hold 2% of their weight in the same names, and IBB returned more over the year.
Avantis U.S. Large Cap Value ETF and iShares Biotechnology ETF.
What they hold in common
By the books each fund has filed, AVLV and IBB hold 2% of their money in the same securities at the same weight.
| Holding | AVLV | IBB |
|---|---|---|
| Gilead Sciences Inc | 1.29% | 6.85% |
| Exelixis Inc | 0.26% | 1.03% |
| United Therapeutics Corp | 0.08% | 1.74% |
| Only in AVLV | Only in IBB |
|---|---|
| Micron Technology Inc 4.57% | Vertex Pharmaceuticals, Inc. 8.09% |
| Amazon.com Inc 3.18% | Amgen, Inc. 7.84% |
| Apple Inc 3.17% | Regeneron Pharmaceuticals, Inc. 4.91% |
| Meta Platforms Inc 2.74% | Argenx SE 3.76% |
| Exxon Mobil Corp 2.59% | Alnylam Pharmaceuticals, Inc. 3.12% |
| Caterpillar Inc 2.53% | Natera, Inc. 2.89% |
| Lam Research Corp 2.52% | Revolution Medicines, Inc. 2.78% |
| Costco Wholesale Corp 2.06% | Biogen, Inc. 2.47% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.
| AVLV Avantis U.S. Large Cap Value ETF | IBB iShares Biotechnology ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Avantis | iShares |
| What it is | U.S. Large Cap Value | Biotechnology |
| Total return, 1 year | +31.0% | +41.5% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +13.5 pts | +24.0 pts |
| Expense ratio | 0.15% | 0.44% |
| Already in the S&P 500 | 84.5% | 35.6% |
| Holdings | 275 | 248 |
AVLV in plain words
AVLV is an index equity fund tracking the U.S. Large Cap Value. Over the year to Sep 11, 2026 it returned +31.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.15% a year. By its holdings filed for May 31, 2026, 84% of the fund by weight is stocks the S&P 500 also holds, across 275 positions, with the top ten at 26.9%.
IBB in plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, AVLV or IBB?
- In the year to Sep 12, 2026, with distributions reinvested, AVLV returned +31.0% and IBB returned +41.5%, so IBB returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, AVLV or IBB?
- AVLV charges 0.15% a year and IBB charges 0.44%, so AVLV is cheaper. Fees come from each fund's prospectus.
- How much do AVLV and IBB overlap with the S&P 500?
- By their latest filed holdings, 84% of AVLV and 36% of IBB by weight is stocks the S&P 500 already holds. Between the two funds, 2% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, AVLV against IBB, data as of Sep 12, 2026. https://etfiq.com/compare/any/AVLV-IBB Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources